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Abstract
Background:  Thromboxane synthase (TxS) metabolizes the cyclooxygenase product,
prostaglandin H(2), into thromboxanes. Some of the thromboxanes are known to be biologically
active on cancer cells. The aim of the study was to investigate the expression of thromboxane
synthases, TBXAS1 and the thromboxane A2 receptor, TBXA2R in a cohort of human breast
cancer patients and also to assess their potential clinical relevance.
Methods: Human breast tumour tissues (n = 120) and non-neoplastic mammary tissues (n = 32)
were studied. Levels of TBXA2R and TBXAS1 transcripts were quantified using quantitative real-
time RT-PCR analysis and correlated with clinical/pathological information including nodal status,
grade, prognosis and long term survival (median follow-up period 120 months).
Results:  Breast tumour tissue expressed higher levels of TBXA2R compared with normal
mammary tissues, although the difference was not statistically significant (p = 0.09). There was no
difference between tumour and normal tissues for TBXAS1. However, TBXA2R expression was
significantly increased in grade 3 tumours(p = 0.006 vs grade 1), while TBXAS1 was significantly
reduced in grade 3 tumours (p = 0.026 vs grade 1 tumours). A similar differential expression
pattern was seen in tumours from patients with different prognosis, in that patients with predicted
poor prognosis had higher, but not statistically different, levels of TBXA2R, and significantly lower
levels of TBXAS1 (p = 0.008). Finally, Kaplan-Meier survival analysis has shown that patients with
high levels of TBXA2R had significantly shorter disease free survival (103.8 (79.1–128.5) months)
compared with those with low levels (123.7 (112.0–135.3)) months, p = 0.043.
Conclusion: Thromboxane synthases are differentially expressed in human breast cancer. While
TBXA2R is highly expressed in aggressive tumours and linked with poor prognosis, TBXAS1 is
expressed at significantly low levels in high grade tumours and tumour patients with poor
prognosis. TBXA2R thus has a significant prognostic value in clinical breast cancer.
Background
Prostaglandin metabolites (eicosanoids) are known to be
selectively active in regulating functions in cells including
cancer cells [1,2]. For example, 12-HETE and 13-HODE
have been shown to act as pro- and anti-cancer eicosa-
noids in a range of cancer cells. Eicosanoids are generated
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from prostaglandins by specific enzymes, some of which
have been shown to be actively involved in the develop-
ment and progression of cancers [3,4]. We have previously
reported aberrant expression of the other groups of pros-
taglandin enzymes 5-, 12-, 15 LOX and COX-2 in human
breast cancer and have demonstrated a distinct pattern of
difference with these enzymes [5].
Thromboxane synthase (TxS) metabolizes the cyclooxyge-
nase product, prostanglandin H(2), into thromboxane
A(2) (TXA(2)), which can cause vessel constriction, plate-
let activation, and aggregation. In human prostate cancer,
thromboxane synthase has been found to be weakly
expressed or absent in normal differentiated luminal or
secretory cells, significantly elevated in less differentiated
or advanced prostate tumors, and markedly increased in
tumors with perineural invasion [6]. Over-expression of
the enzyme in prostate cancer cells increased the cellular
motility [6]. The same over expression of TBXA2R has
been seen in adenocarcinoma and squamous cell carci-
noma of the lung [7].
Thromboxane synthase inhibitors have been shown to
induce apoptosis in glioma cells [8]. In a colorectal
tumour model, cancer cells transduced with TXA(2) syn-
thase cDNA produced faster growing tumours, an effect
that can be reversed by TXA inhibitors [9].
In cancer cells, including breast cancer cells, TBXA2R has
been shown not to influence the adhesion of cancer cells
to matrix proteins [10]. Interestingly, TBXA2R has been
shown to influence angiogenesis in a lung tumour model,
potentially by affecting the migration of endothelial cells
[11]. Thromboxane synthase has been shown to be asso-
ciated with metastasis of renal cell carcinoma [12].
Increased expression of TXA synthase enzymes is a feature
of differentiated monocytoid leukaemia cell lines [13].
Early studies using thromboxane synthase inhibitors in
vivo have failed to show any beneficial effects on metasta-
sis or spread to lymph nodes [14]. Thromboxane (TX)
synthase inhibitors and a TBXA2R receptor antagonist
have been found to inhibit the formation of metastasis
from tail vein injected B16a cells, as well as reduce spon-
taneous metastasis from subcutaneous B16a and Lewis
lung carcinoma tumours [15].
In the current study, we have investigated the level of
expression of Thromboxane A synthase 1, TBXAS1 (other-
wise known as Cyp5 and TXS) and Thromboxane A2
receptor, TBXA2R, in a cohort of human breast cancer
patients. In addition, we have analysed the clinical and
prognostic relevance of both enzymes with the clinical
outcome of the patients over a 10 year period.
Materials and methods
Tissues and patients
The cohort of breast tissues and patients were as previ-
ously described [5,16], except that the median follow-up
for the patients was 120 months. 120 tumour tissues and
32 normal tissues were included in the current study, in
which normal tissues were obtained from the same
patients with breast tumour but were away from tumour
Table 1: Clinical and pathological details of the study cohort
Negative (n =) Positive (n =)
Nodal status n = 65 55
ER status 71 49
Grade Grade 1 Grade 2 Grade 3
n = 23 41 56
Others
Histology Ductal Lobular medullary tubular mucinous
n  = 8 8 1 4 224
TNM staging TNM 1 TNM 2 TNM 3 TNM 4
n = 69 40 7 4
Clinical outcome Disease free With Metastasis With local recur. Died of breast 
Cancer
Died of unrelated 
diseases
n  = 8 17 52 07International Seminars in Surgical Oncology 2005, 2:23 http://www.issoonline.com/content/2/1/23
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margins. The normal background tissues were free from
tumour involvement as confirmed by histological exami-
nation. The pathological data, tumour staging, histologi-
cal types and the initial prognostic index for the patients
were previously described and is given in table 1.
Tissue processing and extraction of RNA and generation of 
cDNA
Tissue processing was as we previously reported [17]. Fro-
zen tissues were sectioned using a cryostat and stored at -
20°C until use. Over 20 frozen sections from the tissues
were homogenised in a RNA extraction solution using a
hand held homogeniser to extract total RNA. The concen-
trations of RNA were quantified using a UV spectropho-
tometer. 1 µg RNA was used to generate cDNA using a
commercially available RT kit (AbGene Laboratories,
Essex, England, UK).
Quantitative analysis of thromboxane synthases
The level of thromboxane synthases transcripts from the
above prepared cDNA was determined using a real-time
quantitative PCR, based on the Amplifluor technology
[18-20]. Briefly, Primers were designed using the Beacon
Designer software (version 2, Palo Alto, California, USA),
to amplify regions of human thromboxane synthases that
have no significant overlap with other known sequences
and that the amplified products span over at least one
intron. Primers for TBXA2R (gene bank accession number
U27325) were 5'tcagctcctggggatcat'3 and 5'actgaacctgaccg-
tacaggtttcgcagcactgtct'3 and for TXA synthase (gene bank
accession number NM_030984) 5'caggtgttggttgagaactt'3
and 5'actgaacctgaccgtacatgtcacgtaaaaacagaacg'3. To one of
the primer was added an additional sequence, known as
the Z sequence (5'actgaacctgaccgtaca'3) which is comple-
mentary to the universal Z probe (Intergen Inc., Oxford,
England, UK). A Taqman detection kit for β-actin was pur-
chased from Perkin-Elmer. The reaction was carried out
using the following: Hot-start Q-master mix (Abgene), 10
pmol of specific forward primer, 1 pmol reverse primer
which has the Z sequence, 10 pmol of FAM-tagged probe
(Intergen Inc.,), and cDNA from approximate 50 ng RNA.
The reaction of was carried out using a IcyclerIQ (Bio-Rad)
which equipment with a optic unit that allows an real
time detection of 96 reactions, using the following condi-
tion: 94°C for 12 minutes, 50 cycles of 94°C for 15 sec-
onds, 55°C for 40 seconds and 72°C for 20 seconds. The
levels of the transcripts were generated from a standard
that were run together with the samples.
Levels of TBXA2R (left) and TBXAS1 (right) in mammary tissues Figure 1
Levels of TBXA2R (left) and TBXAS1 (right) in mammary tissues.International Seminars in Surgical Oncology 2005, 2:23 http://www.issoonline.com/content/2/1/23
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Statistical analysis was carried out using Mann-Whitney U
test and the Kruskal-Wallis test and survival analysis using
Kaplan-Meier survival curve and Univariate analysis
(SPSS12).
Results
Mammary tissues differentially expressed both TBXA2R 
and TBXAS1
Breast tissues expressed both TBXA2R and TBXAS1,
although levels of TBXA2R transcripts tended to be higher
than that of TBXAS1 (figure 1). When normal mammary
tissues and tumour tissues were compared, TBXA2R was
found to be higher in tumour tissues than in normal tis-
sues, although this is not statistically significant (p =
0.09). The levels of TBXAS1 transcript were identical
between normal and tumour tissues (figure 1 left).
TBXA2R and TBXAS1 transcript levels are differentially 
linked to tumour differentiation
In the current study, we have observed that there was sig-
nificant correlation between levels of TBXA2R and
TBXAS1 and tumour grade. As revealed in figure 2 (left),
grade 2 and grade 3 tumours had significantly higher lev-
els of TBXA2R transcript (p = 0.0158 and p = 0.006 vs
grade 1, respectively). Grade 3 tumour had significantly
lower levels of TBXAS1 compared with grade 1 tumours (p
= 0.026). The difference between grade 1 and grade 2 was
not significant.
When levels were compared between node positive and
node negative tumours, no significant difference was seen
with either enzyme (5189 ± 2244 vs 13222 ± 10821 p =
0.48, and 33.2 ± 10 vs 18.5 ± 6.3, p = 0.21, for TBXA2R
and TBXAS1, respectively).
The levels of both molecules were also analysed against
ER status, based on a recent study [21]. As shown in table
2, ER positive tumours had significantly higher levels of
TBXA2R compared with ER negative tumours (p=0.0128).
No significant difference was seen with TBXAS1 in differ-
ent ER status. We also compared the two major histologi-
cal types of breast tumours in the current study, namely
ductal and lobular tumours. As shown in table 3, no sig-
nificant difference was seen between different types.
Table 2: TBXA2R and TBXAS1 levels and ER status
ER (-) ER (+) P value
TBXA2R 2286 ± 1402 21549 ± 16583 p = 0.0128
TBXAS1 16.4 ± 3.6 46.9 ± 18.5 p = 0.12
Levels of TBXA2R (left) and TBXAS1 (right) and their relationship with tumour grade Figure 2
Levels of TBXA2R (left) and TBXAS1 (right) and their relationship with tumour grade. * p < 0.05 vs grade 1.International Seminars in Surgical Oncology 2005, 2:23 http://www.issoonline.com/content/2/1/23
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Thromboxane synthase levels, prognosis and clinical 
outcomes
In the current study, we have used two methods in assess-
ing the prognosis and clinical outcome. The first method
was using a predictive indicator, the Nottingham Prognos-
tic Index (NPI). Patients were divided into three different
prognostic groups, those with predicted good prognosis
(NPI1<3.4), moderate (NPI2 3.4–5.4) and poor progno-
sis (NPI3>5.4). As shown in table 1, patients with pre-
dicted poor prognosis had high levels of TBXA2R,
however, the difference was not significant. It is notewor-
thy that the levels of TBXAS1 transcript were significantly
lower in patients with predicted poor prognosis (table 4).
The second method was to compare levels of the enzyme
transcript based on the clinical outcomes of the patients,
over a 10 year follow-up. This resulted in a sub division of
patients into two groups:- those who remained disease
free or who developed metastasis or local recurrence, and
those who died of breast cancer (excluding non-cancer
related deaths). As shown in table 5, although a high level
of TBXA2R was seen in patients who died of breast cancer,
this was not significant. No significant differences in
TBXA2R and TBXAS1 transcript were seen between groups
with difference clinical outcomes.
Thromboxane synthase and long term survival
The value of TBXA2R and TBXAS1 in assessing long term
survival was analysed using the Kaplan-Meier survival and
Univariate analysis. As seen in figure 3A, high levels of
TBXA2R transcript was associated with a significantly
shorter disease free survival (103.8 (79.1–128.5) months
vs 123.7 (112.0–135.3) month, for patients with high and
low levels, respectively, p = 0.043). There was no signifi-
cant correlation between TBXA2R and the overall survival
(figure 3B), 111.8 (84–139.3) vs 126.1 (115.5–136.7)
months, for patients with high and low TBXA2R, p = 0.43,
figure 3B). The comparison for the subgroups with differ-
ent levels of TBXAS1 returned no significant difference for
the overall survival (p = 0.43) and disease free survival (p
= 0.412).
Discussion
The current study has reported that in human breast can-
cer, transcript levels of thromboxane synthases are aber-
rant. While TBXA2R is normally expressed in tumours and
particularly in aggressive tumours, TBXAS1, however,
showed a very different expression pattern from that of
TBXA2R. Furthermore, TBXA2R levels are associated with
disease free survival.
High levels of TBXA2R and TBXA2Rs have been previously
reported in various tumours including prostate, glioma,
and melanoma. As a result, previous studies have shown
that inhibitors/antagonists to TBXA2R are able to inhibit
metastatic spread. In a liver metastasis model from colon
cancer, the thromboxane synthase inhibitor, sodium oza-
grel at a dose of 15 mg/kg body weight, has been shown
to significantly reduce the rate of metastatic tumours in
the liver, by 57% [22]. Ketoconazole has been shown to
act as an antagonist to both thromboxane synthase and 5-
LOX [23]. Ketoconazole has been shown to reduce lung
metastasis from melanoma cells in an in vivo model. This
together with the current study indicates that TBXA2R, has
a potential impact, via its metabolised product TAX2, on
the metastatic nature of cancer cells.
Metastasis is a complex biological and clinical phenome-
non that involves a number of highly independent yet
crucial steps during its development. Thromboxane syn-
thase has been shown to influence a number of steps in
the process including cell migration, angiogenesis and
apoptosis. Certain eicosanoids (i.e. PGE2) may also stim-
ulate oestrogen synthesis and contribute to the growth of
breast tumours, via pathways including that of aromatase
[24,25]. In addition, eicosanoids also interplay with other
lipids, by way of the peroxisome proliferators activated
receptors (PPAR) [26] which are known to be aberrantly
expressed in breast cancer [19].
The level of expression of thromboxane synthase in gli-
oma cells appears to correlate with the speed of migration
[27]. Similarly, TBXA2R expression has been shown to
influence endothelial cell migration and angiogenesis
[11]. Nevertheless, anomalies exist as some inhibitors to
Table 3: TBXA2R and TBXAS1 levels and relationship with 
histological types
Ductal Lobular P value
TBXA2R 9363 ± 6542 5541 ± 5337 p = 0.67
TBXAS1 23.1 ± 6.1 22.8 ± 13.9 p = 0.34
Table 4: TBXA2R and TBXAS1 levels and prognosis.
Good Moderate Poor
TBXA2R 5188 ± 2244 2561 ± 1206 (p = 0.30) 37614 ± 35470 (p = 0.38)
TBXAS1 33.2 ± 10 20.8 ± 8.2 (p = 0.086) 12.1 ± 6.7 (p = 0.008)
P values are comparison with patients with good prognosis.International Seminars in Surgical Oncology 2005, 2:23 http://www.issoonline.com/content/2/1/23
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thrombaxane synthase, such as dazmegrel, failed to
impact on the growth and weight of fibrosarcoma [28,29].
The other noteworthy observation that can be derived
from the current study is the expression pattern of
TBXAS1, which is in clear contrast to that of TBXA2R.
TBXAS1 is expressed at significantly low levels in high
grade tumours (grade 3) and in patients with predicted
poor clinical outcome (prognostic index NPI greater than
5.4). This indicates that metabolites generated by TBXAS1
may play a very different role in cancer to that of TBXA2R.
There is very little experimental data available on this
aspect. Future studies on the TBXAS1 in vitro and in vivo
would be of significant interest. Finally, the current study
has shown that ER positive tumours have significantly
higher TBXA2R levels than ER negative tumours. Given
the ongoing interest in COX-2 inhibitors and aromatase
inhibitors [30,31], it would be of interest to take into con-
sideration of TBXA2R, ER status as well as aromatase
expression profile, when considering trial design and
choice of therapies.
A number of factors are known to regulate the expression
of TXA synthases. Factors upregulating thromboxane syn-
thase include phorbol ester [34], Activin A [32], Benzo-
quinone derivatives [33] which are interesting as some of
the compounds are dually active on TBXA2R and 5-LOX.
Expression of thromboxane synthase is regulated by cis-
elements, trans-activators and potentially by genomic
methylation [35]. These early observations have an
important bearing when considering the current results.
In conclusion, expression of thromboxane synthases in
clinical human breast cancer is aberrant. While TBXA2R is
commonly expressed in tumours and particularly in
aggressive tumours, TBXAS1, in contrast, showed a very
different expression pattern from that of TBXA2R. Further-
more, TBXA2R levels are associated with disease free sur-
vival, indicating that the receptor is a prognostic factor in
clinical breast cancer.
List of abbreviations
12-HETE: 12-hydroxyeicosatetraenoic acid;
TBXA2R and long term disease free (A) and overall (B) sur- vival Figure 3
TBXA2R and long term disease free (A) and overall (B) sur-
vival. High TBXA2R levels were associated with significant 
shorter disease free survival (A), p = 0.043.
Table 5: TBXA2R and TBXAS1 levels and the clinical outcome.
Disease free With metastasis With local recurrence Patients who died of breast 
cancer
TBXA2R 3405 ± 1503 8660 ± 3661 (p = 0.11) 12882 ± 12873 (p = 0.52) 38611 ± 32930 (p = 0.40)
TBXAS1 22.3 ± 5.5 10.6 ± 4.3 (p = 0.10) 48 ± 47 (p = 0.62) 25.7 ± 12.4 (p = 0.81)
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13-HODE: 13- hydroxyoctadecadienoic acid;
COX-2: cyclooxygenase-2;
ER: oestrogen receptor;
LOX: lipoxygenase;
PGE2: prostaglandin E2;
TBXA2R: thromboxane A2 receptor;
TBXAS1: thromboxane A synthase 1;
TXA2: thromboxane A2;
TxS: Thromboxane synthase;
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